Phase I trial of antigen-specific gene therapy using a recombinant vaccinia virus encoding MUC-1 and IL-2 in MUC-1-positive patients with advanced prostate cancer.

Pantuck, Allan J

Phase I trial of antigen-specific gene therapy using a recombinant vaccinia virus encoding MUC-1 and IL-2 in MUC-1-positive patients with advanced prostate cancer. [electronic resource] - Journal of immunotherapy (Hagerstown, Md. : 1997) - 240-53 p. digital

Publication Type: Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.

1524-9557

10.1097/00002371-200405000-00009 doi


Aged
CD4 Antigens--biosynthesis
CD8 Antigens--biosynthesis
Cancer Vaccines--therapeutic use
Cell Separation
Clinical Trials as Topic
Dose-Response Relationship, Drug
Flow Cytometry
Genetic Therapy--methods
Genetic Vectors
Humans
Immunotherapy
Interleukin-2--genetics
Male
Middle Aged
Mucin-1--genetics
Phenotype
Prostatic Neoplasms--therapy
Reverse Transcriptase Polymerase Chain Reaction
Th1 Cells
Time Factors
Tumor Necrosis Factor-alpha--metabolism
Up-Regulation
Vaccinia virus--genetics